Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | OAsIs trial update: ibrutinib, venetoclax plus obinutuzumab in newly diagnosed MCL

Simon Rule • 7 Dec 2019
ASH 2019
Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Antibodies Ibrutinib Obinutuzumab Rituximab Venetoclax
OAsIs

Simon Rule, MD, Plymouth University, Plymouth, UK, discusses the OAsIs trial (NCT02558816), a multicenter, non-randomized, phase I study designed to assess the safety, tolerability, and efficacy of ibrutinib, venetoclax plus obinutuzumab in newly diagnosed mantle cell lymphoma (MCL). Prof. Rule reveals combination therapies may be relevant for the future, in order to improve outcomes whilst moving away from chemotherapy. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Simon Rule

0:48
Real-world results in the UK for ibrutinib at first relapsed for MCL
Simon Rule • 7 Dec 2019
1:28
Impressive results for R-BAC post BTKi in R/R MCL
Simon Rule • 7 Dec 2019
1:35
Long-term ibrutinib outcomes vs. prior regimens: pooled analysis in R/R MCL
Simon Rule • 6 Dec 2019
3:58
Mantle cell lymphoma update: changing times & latest news
Simon Rule • 20 Jun 2019

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals